A digital protein microarray for COVID-19 cytokine storm monitoring
Yujing Song, Yuxuan Ye, Shiuan‐Haur Su, Andrew Stephens, Tao Cai, Meng Ting Chung, MeiLan K. Han, Michael W. Newstead, Lenar Yessayan, David Frame, H. David Humes, Benjamin H. Singer, Katsuo Kurabayashi
Abstract
), inter-assay repeatability (∼10% CV), and rapid operation providing feedback on the progress of therapy within 4 hours. This test allowed us to perform serial monitoring of two critically ill patients with respiratory failure and to support immunomodulatory therapy using the selective cytopheretic device (SCD). We also observed clear interleukin-6 (IL-6) elevations after receiving tocilizumab (IL-6 inhibitor) while significant cytokine profile variability exists across all critically ill COVID-19 patients and to discover a weak correlation between IL-6 to clinical biomarkers, such as ferritin and C-reactive protein (CRP). Our data revealed large subject-to-subject variability in patients' response to COVID-19, reaffirming the need for a personalized strategy guided by rapid cytokine assays.